Am I safe to predict that the EMA 2b trial will be double blinded. But what about number of patients. This is make or break time because what our EMA study looks like is going to have so much weight in the FDA meeting. This is where management's rubber meets the road.
ANP Price at posting:
20.0¢ Sentiment: Hold Disclosure: Held
